Def6 Restrains Osteoclastogenesis and Inflammatory Bone Resorption.

Area of Science:

• Immunology
• Bone Biology
• Rheumatology

Background:

• Osteoclast-mediated bone resorption drives morbidity in inflammatory disorders like rheumatoid arthritis (RA).
• Mechanisms regulating osteoclastogenesis in inflammation are complex and not fully understood.

Purpose of the Study:

• To identify novel regulators of osteoclastogenesis in physiological and inflammatory conditions.
• To investigate the role of differentially expressed in FDCP 6 homolog (Def6) in osteoclast formation and bone resorption.

Main Methods:

• Utilized Def6-deficient mice to study osteoclastogenesis and bone resorption.
• Assessed TNF-α-induced osteoclastogenesis in vitro and in vivo.
• Analyzed Def6 expression and osteoclastogenic capacity in rheumatoid arthritis patient samples.

Main Results:

• Def6 deficiency enhanced osteoclast precursor sensitivity and increased TNF-α-induced osteoclastogenesis.
• Def6 deficiency led to enhanced bone resorption in an inflammatory osteolysis model.
• In RA patients, lower Def6 expression correlated with higher TNF-α levels and increased osteoclastogenic capacity.

Conclusions:

• Def6 acts as a novel inhibitor of osteoclastogenesis in both physiological and inflammatory settings.
• Def6 suppresses key osteoclastogenic factors (NFATc1, Blimp-1, c-Fos) via an IFN-β feedback loop.
• The Def6-dependent pathway presents a potential therapeutic target for preventing pathological bone destruction in RA.